The Greatest Guide To P-gb-IN-1
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To judge a number of intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Main demo objectives ended up to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositi